A Phase 1 clinical study of HexaPro/HD-MAP COVID-19 vaccine
Latest Information Update: 08 Jun 2023
At a glance
- Drugs HexaPro (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Vaxxas
- 05 Jun 2023 According to a Vaxxas Media Release, Interim study results will be presented at the 2023 BIO International Convention.
- 05 Jun 2023 Inteirm results presented in a Vaxxas Media Release.
- 08 Nov 2022 According to a Vaxxas media release, this trial is being conducted in Australia at the University of the Sunshine Coast Sippy Downs clinical research location.